Teladoc Health had its Relative Strength (RS) Rating upgraded from 62 to 79 Friday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 as they launch their biggest price moves. See if Teladoc Health can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
Teladoc Health is still within a buy range after climbing above a 12.43 buy point in a cup without handle. Once a stock moves 5% or higher beyond the initial entry, it's considered extended and out of buy range.
The company reported negative growth for both the top and bottom lines last quarter. The company is expected to release its next quarterly numbers on or around Feb. 26.
The company holds the No. 8 rank among its peers in the Computer Software-Medical industry group. Doximity, Waystar Holding and Veeva Systems Cl A are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
